AR016751A1 - METHOD FOR INHIBITING THE RELEASE OF THE BETA-AMYLOID PEPTIDE IN A CELL, PHARMACEUTICAL COMPOSITION AND USEFUL COMPOUNDS IN THIS METHOD - Google Patents

METHOD FOR INHIBITING THE RELEASE OF THE BETA-AMYLOID PEPTIDE IN A CELL, PHARMACEUTICAL COMPOSITION AND USEFUL COMPOUNDS IN THIS METHOD

Info

Publication number
AR016751A1
AR016751A1 ARP970105393A ARP970105393A AR016751A1 AR 016751 A1 AR016751 A1 AR 016751A1 AR P970105393 A ARP970105393 A AR P970105393A AR P970105393 A ARP970105393 A AR P970105393A AR 016751 A1 AR016751 A1 AR 016751A1
Authority
AR
Argentina
Prior art keywords
beta
release
inhibiting
cell
pharmaceutical composition
Prior art date
Application number
ARP970105393A
Other languages
Spanish (es)
Original Assignee
Athena Neurosciences Inc
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athena Neurosciences Inc, Lilly Co Eli filed Critical Athena Neurosciences Inc
Publication of AR016751A1 publication Critical patent/AR016751A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se describen compuestos que inhiben la liberacion de péptidos Beta-amiloides y/o sus síntesis, y por consiguiente que tienen utilidad paratratar la enfermedad de Alzheimer. Asimismo se describen composiciones farmacéuticas quecomprende un compuesto que inhibe la liberacion de péptidosBeta-amiloides y/o sus síntesis así como también métodos para tratar la enfermedad de Alzheimer tanto profiláctica como terapéuticamente con dichascomposiciones farmacéuticas.Compounds that inhibit the release of beta-amyloid peptides and / or their syntheses are described, and therefore have utility to treat Alzheimer's disease. Also described are pharmaceutical compositions comprising a compound that inhibits the release of Beta-amyloid peptides and / or their syntheses as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with said pharmaceutical compositions.

ARP970105393A 1996-11-22 1997-11-18 METHOD FOR INHIBITING THE RELEASE OF THE BETA-AMYLOID PEPTIDE IN A CELL, PHARMACEUTICAL COMPOSITION AND USEFUL COMPOUNDS IN THIS METHOD AR016751A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75544296A 1996-11-22 1996-11-22
US80742797A 1997-02-28 1997-02-28
US80852897A 1997-02-28 1997-02-28
US80752897A 1997-02-28 1997-02-28

Publications (1)

Publication Number Publication Date
AR016751A1 true AR016751A1 (en) 2001-08-01

Family

ID=27505670

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970105393A AR016751A1 (en) 1996-11-22 1997-11-18 METHOD FOR INHIBITING THE RELEASE OF THE BETA-AMYLOID PEPTIDE IN A CELL, PHARMACEUTICAL COMPOSITION AND USEFUL COMPOUNDS IN THIS METHOD

Country Status (21)

Country Link
EP (1) EP0942924A2 (en)
JP (1) JP2001503782A (en)
KR (1) KR20000069064A (en)
CN (1) CN1238779A (en)
AR (1) AR016751A1 (en)
AU (1) AU5356198A (en)
BR (1) BR9713400A (en)
CA (1) CA2267634A1 (en)
CO (1) CO4910156A1 (en)
CZ (1) CZ122899A3 (en)
EA (1) EA199900490A1 (en)
HR (1) HRP970627A2 (en)
HU (1) HUP0100270A3 (en)
ID (1) ID22044A (en)
IL (1) IL129083A0 (en)
NO (1) NO992368L (en)
NZ (1) NZ334690A (en)
PE (1) PE16999A1 (en)
TR (3) TR199901133T2 (en)
WO (1) WO1998022494A2 (en)
YU (1) YU46097A (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19616486C5 (en) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Method for lowering the blood glucose level in mammals
US6191166B1 (en) * 1997-11-21 2001-02-20 Elan Pharmaceuticals, Inc. Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
DE19823831A1 (en) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim New pharmaceutical use of isoleucyl thiazolidide and its salts
AU4707999A (en) * 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
AU4710499A (en) * 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use ofsuch compounds
US6958330B1 (en) 1998-06-22 2005-10-25 Elan Pharmaceuticals, Inc. Polycyclic α-amino-ε-caprolactams and related compounds
AU4710199A (en) * 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
DE19828114A1 (en) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs of unstable inhibitors of dipeptidyl peptidase IV
DE19828113A1 (en) * 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs of Dipeptidyl Peptidase IV Inhibitors
DE19834591A1 (en) 1998-07-31 2000-02-03 Probiodrug Ges Fuer Arzneim Use of substances that decrease the activity of dipeptidyl peptidase IV to increase blood sugar levels, e.g. for treating hypoglycemia
US6486350B1 (en) 1998-09-30 2002-11-26 Elan Pharmaceuticals Inc. Biological reagents and methods for determining the mechanism in the generation of β-amyloid peptide
US6737038B1 (en) 1998-11-12 2004-05-18 Bristol-Myers Squibb Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
AU772575B2 (en) 1998-12-10 2004-04-29 F. Hoffmann-La Roche Ag Procollagen C-proteinase inhibitors
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
TR200103427T2 (en) * 1999-05-07 2002-10-21 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors.
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
DE19926233C1 (en) 1999-06-10 2000-10-19 Probiodrug Ges Fuer Arzneim Production of thiazolidine, useful as pharmaceutical intermediate, comprises reacting hexamethylenetetramine with cysteamine
DE19940130A1 (en) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim New effectors of Dipeptidyl Peptidase IV for topical use
CA2388750A1 (en) * 1999-11-09 2001-05-17 James Edmund Audia .beta.-aminoacid compounds useful for inhibiting .beta.-amyloid peptide release and/or its synthesis
DE60137216D1 (en) 2000-03-31 2009-02-12 Prosidion Ltd IMPROVING THE ACTIVITY OF THE ISLAND CELLS IN DIABETES MELLITUS AND ITS PREVENTION
WO2001087354A2 (en) 2000-05-17 2001-11-22 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands for diagnostic imaging
BR0106717A (en) 2000-06-01 2002-04-16 Bristol Myers Squibb Pharma Co Compounds, pharmaceutical composition and uses of innovative lactam compounds
FR2832152A1 (en) * 2001-11-09 2003-05-16 Aventis Pharma Sa New 2-amino-thiazoline derivatives having inducible NO-synthase inhibiting activity, useful for treating Parkinson's, cerebral disorders, migraines, depression, diabetes
GB0016681D0 (en) 2000-07-06 2000-08-23 Merck Sharp & Dohme Therapeutic compounds
US6432944B1 (en) 2000-07-06 2002-08-13 Bristol-Myers Squibb Company Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
US7132104B1 (en) 2000-10-27 2006-11-07 Probiodrug Ag Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
US6890905B2 (en) 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
DE10150203A1 (en) 2001-10-12 2003-04-17 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitor in treatment of cancer
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
AR039059A1 (en) 2001-08-06 2005-02-09 Sanofi Aventis COMPOUND DERIVED FROM ACILAMINOTIAZOL, ITS USE, PROCEDURES TO PREPARE IT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, AND INTERMEDIARY COMPOUNDS
FR2840899B1 (en) * 2002-06-12 2005-02-25 Sanofi Synthelabo ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
DE10143840A1 (en) * 2001-09-06 2003-03-27 Probiodrug Ag New acylated hydroxamates useful for the treatment of e.g. wound healing
ES2256583T3 (en) 2001-11-09 2006-07-16 Aventis Pharma S.A. DERIVATIVES OF 2-AMINO-TIAZOLINE AND ITS USE AS INHIBITORS OF THE INDUCIBLE NON-SYNTHEASE.
DE20220238U1 (en) 2002-02-28 2003-05-08 Probiodrug AG, 06120 Halle Glutaminyl based DPIV inhibitors
KR101145252B1 (en) * 2003-01-08 2012-05-24 유니버시티 오브 워싱톤 Antibacterial agents
KR20100106630A (en) 2003-05-05 2010-10-01 프로비오드룩 아게 Use of effectors of glutaminyl and glutamate cyclases
JP4806628B2 (en) 2003-05-05 2011-11-02 プロビオドルグ エージー Glutaminyl cyclase inhibitor
EP1666068A4 (en) * 2003-09-24 2010-08-04 Santen Pharmaceutical Co Ltd Remedy for eye diseases accompanied by optic nerve injuries
BRPI0415409A (en) 2003-10-15 2006-12-05 Probiodrug Ag use of glutaminyl and glutamate cyclase effectors
EP2662353A3 (en) 2007-06-12 2014-04-02 Achaogen, Inc. Antibacterial agents
EP2062909A1 (en) * 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Peptide production and purification process
BG110141A (en) 2008-05-23 2009-12-31 "Софарма" Ад Galanthamine derivatives, methods for their obtaining and use
WO2013170165A1 (en) 2012-05-10 2013-11-14 Achaogen, Inc. Antibacterial agents
WO2017004560A1 (en) * 2015-07-02 2017-01-05 The Regents Of The University Of California Methods and compositions for amyloid aggregates
WO2022150314A1 (en) * 2021-01-05 2022-07-14 Southern Research Institute Modulators of programmed death-ligand-1
WO2024076635A2 (en) * 2022-10-05 2024-04-11 Buck Institute For Research On Aging Suppressors of site iq electron leak and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97428A0 (en) * 1990-03-05 1992-06-21 Cephalon Inc Chymotrypsin-like proteases and their inhibitors
WO1995013084A1 (en) * 1992-05-11 1995-05-18 Miles Inc. Cathepsin d is an amyloidogenic protease in alzheimer's disease
CZ184194A3 (en) * 1993-08-09 1995-03-15 Lilly Co Eli Aspartylprotease inhibitor and method of identifying thereof
PT721449E (en) * 1993-10-01 2002-06-28 Merrell Pharma Inc BETA-AMYLOID PROTEIN PRODUCTION INHIBITORS
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
JPH11506923A (en) * 1995-06-06 1999-06-22 アセナ ニューロサイエンシーズ，インコーポレイテッド New cathepsins and methods and compositions for their inhibition

Also Published As

Publication number Publication date
HUP0100270A2 (en) 2001-08-28
CN1238779A (en) 1999-12-15
JP2001503782A (en) 2001-03-21
CZ122899A3 (en) 1999-10-13
WO1998022494A3 (en) 1998-11-26
TR199902938T2 (en) 2002-06-21
TR199902937T2 (en) 2001-01-22
AU5356198A (en) 1998-06-10
EP0942924A2 (en) 1999-09-22
NO992368L (en) 1999-06-21
IL129083A0 (en) 2000-02-17
PE16999A1 (en) 1999-02-19
CA2267634A1 (en) 1998-05-28
YU46097A (en) 2000-10-30
NO992368D0 (en) 1999-05-14
ID22044A (en) 1999-08-26
NZ334690A (en) 2001-09-28
EA199900490A1 (en) 2000-02-28
TR199901133T2 (en) 1999-07-21
WO1998022494A2 (en) 1998-05-28
HRP970627A2 (en) 1998-08-31
KR20000069064A (en) 2000-11-25
HUP0100270A3 (en) 2001-09-28
BR9713400A (en) 2000-01-25
CO4910156A1 (en) 2000-04-24

Similar Documents

Publication Publication Date Title
AR016751A1 (en) METHOD FOR INHIBITING THE RELEASE OF THE BETA-AMYLOID PEPTIDE IN A CELL, PHARMACEUTICAL COMPOSITION AND USEFUL COMPOUNDS IN THIS METHOD
BR9714517A (en) Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising them and processes to inhibit beta-amyloid peptide release and / or its synthesis by using such compounds
DE69733272D1 (en) N- (ARYL / HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF AND METHODS FOR INHIBITING THE BETA-AMYLOID EXTRACTION AND / OR THEIR SYNTHESIS USING THESE COMPOUNDS
EA199900778A1 (en) HETEROCYCLIC COMPOUNDS AND THEIR USE TO INHIBIT β-AMYLOID PEPTIDE
PE20020802A1 (en) LACTAM COMPOUND AS INHIBITOR OF THE RELEASE OF THE ß-AMYLOID PEPTIDE
ES2178000T3 (en) COMPOSITIONS AND METHODS TO TREAT INFECTIONS USING INDOLICIDINE ANALOGS.
BR9502707A (en) Compound pharmaceutical composition and method for treating a condition
ES2176600T3 (en) DERIVATIVE OF PROPIOFENONE AND PROCEDURES FOR PREPARATION.
BR9714064A (en) Pharmaceutical composition
BG101841A (en) Cellular adhesion inhibitors
BG104599A (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
TR199701073T1 (en) Protein kinase C inhibitors.
NZ223400A (en) Dental composition containing kappa-caseino-glycopeptides
BRPI0113286B8 (en) substituted pyrazoles and pharmaceutical composition comprising the same.
ID29393A (en) COMPOSITION OF CANCER TREATMENT AND METHOD OF USING NATURAL PLANT ESENSIL OILS
ATE264692T1 (en) USE OF NO SYNTHASE INHIBITORS AND CAUGHTERS OF REACTIVE OXYGEN FORMS TO TREAT ISCHEMIA
MX9204268A (en) A COMPOSITION FOR THE PROLONGED AND CONTROLLED RELEASE OF MEDICINAL SUBSTANCES AND A PROCESS TO PREPARE THE SAME.
PT735890E (en) 2 ', 3'-DIDESOXY-INOSINE AND HYDROXYCARBAMIDE MIXTURES FOR INHIBITION OF RETROVIRAL DISSEMINATION
BG103995A (en) Reverse hydroxamate inhibitors of matrix metalloprreverse hydroxamate inhibitors of matrix metallprooteinases teinases
DE69530403D1 (en) KERATINOCYTE GROWTH FACTOR ANALOGS
ATE273690T1 (en) COMPOSITION FOR SKIN DISINFECTING
AR003589A1 (en) USE OF AN EFFECTIVE AMOUNT OF AT LEAST ONE PEPTIDE IN A COSMETIC COMPOSITION OR FOR THE PREPARATION OF A MEDICATION INTENDED TO PARATRATE INFLAMMATION, AND A COSMETIC TREATMENT PROCEDURE THROUGH A COSMETIC COMPOSITION CONTAINING SUCH PEPTIDE.
BR9913072A (en) Azacyclic ring systems, pharmaceutical composition, and process to induce analgesia
ES2170143T3 (en) COMPOSITIONS THAT INCLUDE HALOFANTRINE IN A SPECIAL FORM.
DK1207870T3 (en) Pharmaceutical compositions containing N-palmitoylethanolamide and its use

Legal Events

Date Code Title Description
FA Abandonment or withdrawal